Back

Nakhle Saba, MD, and colleagues explored treatment discontinuation patterns with BTK inhibitors in first-line chronic lymphocytic leukemia.

Real-World Treatment Patterns With First-Line BTK Inhibitors in CLL

Episodes

Specialty:

All

Year:

All

Image Credit: © Oleksandr - stock.adobe.com

Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL

ByErin Mulvey, MD

August 4th 2026

Erin Mulvey, MD, discusses real-world time to treatment discontinuation data for first-line zanubrutinib compared with other BTK inhibitors in CLL.

Real-world data showed zanubrutinib was associated with longer time to treatment discontinuation and higher persistence vs acalabrutinib or ibrutinib in first-line CLL.

Real-World Analysis Sheds Light on Treatment Discontinuation With Covalent BTK Inhibitors in First-Line CLL

ByChris Ryan

June 18th 2026

Real-world data showed zanubrutinib was associated with longer time to treatment discontinuation and higher persistence vs acalabrutinib or ibrutinib in first-line CLL.

Real-World Treatment Patterns With First-Line BTK Inhibitors in CLL

Episodes

Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL

Real-World Analysis Sheds Light on Treatment Discontinuation With Covalent BTK Inhibitors in First-Line CLL

Trending on OncLive

FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer

FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas

Sapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera

OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026

Dr Cohen on FcRH5 as a Therapeutic Target in Multiple Myeloma